Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro

详细信息    查看全文

• 作者：An-Cheng Huang^a ; ¹ ; Mei-Due Yang^b ; ¹ ; Yung-Ting Hsiao^c ; Tzu-Shun Lin^d ; Yi-Shih Ma^e ; ^f ; Shu-Fen Peng^c ; Te-Chun Hsia^g ; ^h ; Yih-Dih Chengⁱ ; ^j ; Chao-Lin Kuo^k ; ^{clclkuo@mail.cmu.edu.tw} ; Jing-Gung Chung^c ; ^l ; ^{jgchung@mail.cmu.edu.tw}
• 关键词：Chan Su ; Bufalin ; Gefitinib resistance ; NSCLC ; Migration ; Invasion
• 刊名：Journal of Ethnopharmacology
• 出版年：2016
• 出版时间：24 December 2016
• 年：2016
• 卷：194
• 期：Complete
• 页码：1043-1050
• 全文大小：1004 K
• 卷排序：194

文摘

Bufalin, a component of Chan Su (frog), has been shown to have biological activities including anti-tumor effects. Gefitinib has been used as an anti-cancer drug in lung cancer patients; however, some patients eventually become gefitinib resistant.Aim of the studyIn this study, we investigated anti-metastasis effects of bufalin in gefitinib resistant NCI-H460 lung cancer cells.Materials and methodsThe effects of the bufalin in gefitinib resistant NCI-H460 lung cancer cells were investigated on cell viability using flow cytometry. The adhesion capacity, wound healing assay, invasion and migration assay, and Western blot analysis were used to understand the molecular mechanisms in this studyResultsUnder sub-lethal concentrations (from 2.5 up to 10 nM), bufalin significantly inhibits cell adhension, migration and invasion nature of gefitinib resistant H460 cells. Western blotting assay revealed that bufalin depressed some of the key metastasis-related proteins, such as SOS-1, MMP-2 and Rho A underwent significant reduction. Phosphorylated Focal adhesion kinase (p-FAK), phosphorylated extracellular signal-regulated kinase (p-ERK1/2), Ras and E-cadherin were significantly reduced at 48 h treatment. However, phosphorylated p38 (p-p38), phosphorylated c-Jun NH2-terminal kinase (p-JNK1/2) and NF-κBp65 were increased.ConclusionsBased on these observations, we suggest that bufalin can be used in anti-metastasis of gefitinib resistant NCI-H460 lung cancer cells in the future.